{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:25:04Z","timestamp":1786119904887,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/wad.0b013e31821764ce","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T08:35:24Z","timestamp":1302856524000},"page":"50-54","source":"Crossref","is-referenced-by-count":9,"title":["Relation Between Insulin, Insulin-related Factors, and Plasma Amyloid Beta Peptide Levels at Midlife in a Population-based Study"],"prefix":"10.1097","volume":"26","author":[{"given":"Mary K.","family":"Townsend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia I.","family":"Okereke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis J.","family":"Selkoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Grodstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ana.410370303","article-title":"Evidence that A beta 42 is the real culprit in Alzheimers disease.","volume":"37","author":"Younkin","year":"1995","journal-title":"Ann Neurol"},{"key":"R2-7-20210128","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics.","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"R3-7-20210128","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ana.21559","article-title":"Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.","volume":"65","author":"Fagan","year":"2009","journal-title":"Ann Neurol"},{"key":"R4-7-20210128","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ana.410370305","article-title":"Amyloid beta protein (A beta) deposition: a beta 42 (43) precedes A beta 40 in Down syndrome.","volume":"37","author":"Iwatsubo","year":"1995","journal-title":"Ann Neurol"},{"key":"R5-7-20210128","doi-asserted-by":"crossref","first-page":"32730","DOI":"10.1074\/jbc.273.49.32730","article-title":"Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation.","volume":"273","author":"Qiu","year":"1998","journal-title":"J Biol Chem"},{"key":"R6-7-20210128","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1006\/bbrc.1998.8276","article-title":"Insulin acts intracellularly on proteasomes through insulin-degrading enzyme.","volume":"244","author":"Duckworth","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"R7-7-20210128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults.","volume":"13","author":"Reger","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"R8-7-20210128","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/01.wnl.0000216274.58185.09","article-title":"Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease.","volume":"66","author":"Kulstad","year":"2006","journal-title":"Neurology"},{"key":"R9-7-20210128","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1523\/JNEUROSCI.0664-05.2005","article-title":"Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimers disease.","volume":"25","author":"Hartman","year":"2005","journal-title":"J Neurosci"},{"key":"R10-7-20210128","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1523\/JNEUROSCI.21-02-00372.2001","article-title":"Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimers disease.","volume":"21","author":"Kawarabayashi","year":"2001","journal-title":"J Neurosci"},{"key":"R11-7-20210128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNF.0b013e3181cb577a","article-title":"Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.","volume":"33","author":"Siemers","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"R12-7-20210128","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/archneur.64.3.354","article-title":"Association of low plasma Abeta42Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.","volume":"64","author":"Graff-Radford","year":"2007","journal-title":"Arch Neurol"},{"key":"R13-7-20210128","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1212\/WNL.0b013e3181b78448","article-title":"Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study.","volume":"73","author":"Lambert","year":"2009","journal-title":"Neurology"},{"key":"R14-7-20210128","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1212\/01.wnl.0000306696.82017.66","article-title":"Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study.","volume":"70","author":"Lopez","year":"2008","journal-title":"Neurology"},{"key":"R15-7-20210128","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archneurol.2009.207","article-title":"Ten-year change in plasma amyloid beta levels and late-life cognitive decline.","volume":"66","author":"Okereke","year":"2009","journal-title":"Arch Neurol"},{"key":"R16-7-20210128","doi-asserted-by":"crossref","first-page":"14052","DOI":"10.1073\/pnas.0805902105","article-title":"Peripheral Abeta subspecies as risk biomarkers of Alzheimers disease.","volume":"105","author":"Schupf","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R17-7-20210128","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1474-4422(06)70501-4","article-title":"Plasma Abeta(1 to 40) and Abeta(1 to 42) and the risk of dementia: a prospective case-cohort study.","volume":"5","author":"van Oijen","year":"2006","journal-title":"Lancet Neurol"},{"key":"R18-7-20210128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1749-6632.2000.tb05554.x","article-title":"Toward a comprehensive theory for Alzheimers disease. Hypothesis: Alzheimers disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein.","volume":"924","author":"Selkoe","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"R19-7-20210128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3233\/JAD-2009-0948","article-title":"Performance characteristics of plasma amyloid-beta 40 and 42 assays.","volume":"16","author":"Okereke","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"R20-7-20210128","first-page":"570","article-title":"The validity of recalled weight among younger women.","volume":"19","author":"Troy","year":"1995","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R21-7-20210128","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00001648-199011000-00009","article-title":"Validity of self-reported waist and hip circumferences in men and women.","volume":"1","author":"Rimm","year":"1990","journal-title":"Epidemiology"},{"key":"R22-7-20210128","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/ije\/23.5.991","article-title":"Reproducibility and validity of a self-administered physical activity questionnaire.","volume":"23","author":"Wolf","year":"1994","journal-title":"Int J Epidemiol"},{"key":"R23-7-20210128","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/oxfordjournals.aje.a115960","article-title":"The assessment of alcohol consumption by a simple self-administered questionnaire.","volume":"133","author":"Giovannucci","year":"1991","journal-title":"Am J Epidemiol"},{"key":"R24-7-20210128","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2337\/diab.46.6.1001","article-title":"Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study.","volume":"46","author":"Perseghin","year":"1997","journal-title":"Diabetes"},{"key":"R25-7-20210128","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1172\/JCI119628","article-title":"Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR).","volume":"100","author":"Ferrannini","year":"1997","journal-title":"J Clin Invest"},{"key":"R26-7-20210128","doi-asserted-by":"crossref","first-page":"H2009","DOI":"10.1152\/ajpheart.00522.2007","article-title":"Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance.","volume":"293","author":"Cooper","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R27-7-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.med.49.1.235","article-title":"Exercise, glucose transport, and insulin sensitivity.","volume":"49","author":"Goodyear","year":"1998","journal-title":"Annu Rev Med"},{"key":"R28-7-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1474-4422(04)00681-7","article-title":"Insulin and neurodegenerative disease: shared and specific mechanisms.","volume":"3","author":"Craft","year":"2004","journal-title":"Lancet Neurol"},{"key":"R29-7-20210128","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1073\/pnas.91.11.4766","article-title":"Advanced glycation end products contribute to amyloidosis in Alzheimer disease.","volume":"91","author":"Vitek","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R30-7-20210128","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","article-title":"Plasma Abeta40 and Abeta42 and Alzheimers disease: relation to age, mortality, and risk.","volume":"61","author":"Mayeux","year":"2003","journal-title":"Neurology"},{"key":"R31-7-20210128","doi-asserted-by":"crossref","first-page":"10706","DOI":"10.1523\/JNEUROSCI.2637-09.2009","article-title":"Characterizing the appearance and growth of amyloid plaques in APPPS1 mice.","volume":"29","author":"Yan","year":"2009","journal-title":"J Neurosci"}],"container-title":["Alzheimer Disease & Associated Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002093-201201000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:23:50Z","timestamp":1786044230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002093-201201000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/wad.0b013e31821764ce","relation":{},"ISSN":["0893-0341"],"issn-type":[{"value":"0893-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}